Brookings panel of experts lays out case for onshoring manufacturing
As the US and Europe continue to consider onshoring pharma manufacturing to shore up the international supply chain, a panel of experts, hosted by the Brookings Institution, addressed how to shore up supplies and resiliency as drug shortages and other supply issues persist after the pandemic’s initial impact.
Speaking on lessons learned from the pandemic, Tom Bollyky, director of the Global Health Program and Senior Fellow for Global Health, Economics and Development at the Council on Foreign Relation, said that while there was general success in moving billions of doses of the Covid-19 vaccine once it became more widely available, there were still some difficulties. More than two-thirds of countries had export restrictions on essential medical products during the pandemic, Bollyky said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters